Quant'AbondanceL'abondance, quantifiée.

Actualités

Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.

23,585 signal articles · 322 in last 24h · 112,405 total before filter · latest 55m ago
322last 24h
2137last 7d
379● bullish (7d)
187● bearish (7d)
204publishers
AllMacro296Earnings1215M&A90Regulatory23Product13Analyst20
✕ clear all filtersticker: BSXSentiment:bullishneutralbearishshow all (incl. clickbait)
Boston Scientific Q2 Earnings Call Highlights
MarketBeat14d agoneutral
Boston Scientific Q2 Earnings Call Highlights

Boston Scientific (NYSE:BSX) reported second-quarter 2026 revenue growth at the high end of its guidance range and adjusted earnings per share above expectations, but lowered its full-year outlook as it faces slowing demand in its WATCHMAN left atrial appendage closure business and increased competi

Boston Scientific (NYSE:BSX) Surprises With Q2 CY2026 Sales But Quarterly Revenue Guidance Misses Expectations
StockStory14d agobearish
Boston Scientific (NYSE:BSX) Surprises With Q2 CY2026 Sales But Quarterly Revenue Guidance Misses Expectations

Medical device company Boston Scientific (NYSE:BSX) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 7.5% year on year to $5.44 billion. On the other hand, next quarter’s revenue guidance of $5.27 billion was less impressive, coming in 2.2% below analysts’ estimates. Its non-GAAP profit of $0.86 per share was 3.8% above analysts’ consensus estimates.